Biology and Medical Engineering
Cure8 research brief
Why This Matters
The study suggests gut fungi — especially Candida — can worsen IBD-like inflammation by driving Th17 immune responses through Dectin‑1/Syk signalling. Understanding this pathway could guide future research on antifungal strategies or immune-targeted therapies for IBD.
Who Should Pay Attention
Researchers studying the gut microbiome or immune pathways in IBD; clinicians interested in mechanisms of mucosal inflammation; translational scientists exploring antifungal or innate-immune–targeted approaches.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
The authors used DSS-induced acute and chronic colitis mouse models, antifungal treatment, Candida albicans recolonisation, Dectin-1 (Clec7a) knockout mice, and a Syk inhibitor (R788) to test whether fungal components drive Th17 polarization and worsen colitis.
They report higher fungal loads (including Candida) in colitis, that antifungal clearance reduced Th17 infiltration and colitis severity, and that effects were reversed by recolonisation with C. albicans.
Mechanistic experiments described include in vitro co-culture of naïve CD4+ T cells with bone marrow–derived dendritic cells and stimulation with fungal β‑glucan; these implicate Dectin-1/Syk/CARD9 signalling in dendritic-cell production of IL‑6/IL‑23 and subsequent Th17 polarization.
Keep In Mind
This is based on the article abstract and describes preclinical (mouse and in vitro) research. It does not provide evidence that antifungal treatment improves IBD outcomes in patients.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationBiology and Medical Engineering
AuthorsGang Liu, Jia Wang, Alena Mikalaeuna Vasiukevich +1 more
InstitutionBelarusian State University
Study typeArticle
Indexed viaOpenAlex
Source typeResearch paper
PublishedNov 7, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Chemokine Ligand-3 (CCL3) as a Novel Mediator of Inflammatory Bowel Disease Activity.
Identifies a molecule (CCL3) linked to more severe inflammation in IBD tissues, which could help researchers develop new biomarkers or treatments targeting immune-cell recruitment and polarization.
Nitrogen dioxide exposure promotes CD8+T cell infiltration and contributes to increased susceptibility to ulcerative colitis: An integrative multi‑omics, artificial intelligence, and mouse model study.
The study suggests that air pollutant NO2 may promote a perforin-producing CD8+ T cell response linked to colonic inflammation in UC and highlights CDC25B as a potential mechanistic link—information that could guide...
Sodium acetate attenuates ulcerative colitis by reducing intestinal epithelial apoptosis and remodeling gut microbiota
The study suggests acetate (sodium acetate) can protect intestinal cells and reshape the gut microbiota in preclinical models of ulcerative colitis, pointing to a potential microbiome-linked therapeutic avenue that might...